Douglas R. Lowy
#30,194
Most Influential Person Now
American cancer researcher
Douglas R. Lowy's AcademicInfluence.com Rankings
Douglas R. Lowyphilosophy Degrees
Philosophy
#3486
World Rank
#5626
Historical Rank
#1107
USA Rank
Logic
#1246
World Rank
#1942
Historical Rank
#382
USA Rank
Download Badge
Philosophy
Douglas R. Lowy's Degrees
- Doctorate Medicine New York University
Why Is Douglas R. Lowy Influential?
(Suggest an Edit or Addition)According to Wikipedia, Douglas R. Lowy is the current Acting Director and Principal Deputy Director of the U.S. National Cancer Institute and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy served as Acting Director of NCI between April 2015 and October 2017 following the resignation of Harold E. Varmus, M.D., and again between April and November 2019, while Director Norman Sharpless served as the Acting Commissioner of the U.S. Food and Drug Administration. He resumed the role of Acting Director on May 1, 2022, when Sharpless stepped down until October 3, 2022 when Monica Bertagnolli was appointed Director. He resumed the role again in November 2023 after Bertagnolli resigned to serve as director of the National Institutes of Health.
Douglas R. Lowy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mechanism of activation of a human oncogene (1982) (1244)
- Function and regulation of ras. (1993) (1190)
- Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. (1992) (1119)
- Toward a Shared Vision for Cancer Genomic Data. (2016) (1017)
- HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. (1989) (906)
- Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles (1993) (640)
- The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes (1981) (625)
- Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. (2001) (620)
- Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection (1995) (612)
- Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis (1992) (581)
- Murine Leukemia Virus: High-Frequency Activation in vitro by 5-Iododeoxyuridine and 5-Bromodeoxyuridine (1971) (571)
- Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. (2007) (571)
- Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus (1982) (540)
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality. (2020) (532)
- The p21 ras C-terminus is required for transformation and membrane association (1984) (517)
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women (2008) (482)
- Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan (2007) (481)
- Efficient Intracellular Assembly of Papillomaviral Vectors (2004) (473)
- Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. (1988) (451)
- Prophylactic human papillomavirus vaccines. (2006) (439)
- Carrageenan Is a Potent Inhibitor of Papillomavirus Infection (2006) (417)
- Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica (2013) (412)
- Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. (1987) (400)
- A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. (1994) (394)
- E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases (2004) (387)
- Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. (2004) (356)
- Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. (1998) (355)
- Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. (1996) (341)
- Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences. (1981) (331)
- Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. (1989) (328)
- Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection (2006) (328)
- Arrangement of L2 within the Papillomavirus Capsid (2008) (327)
- Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. (1984) (321)
- Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus (1980) (320)
- Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA (1987) (320)
- The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. (1990) (319)
- In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype (1996) (305)
- High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). (2001) (296)
- Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells1 (2001) (294)
- Genital human papillomavirus infection. (1994) (284)
- Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas (1982) (281)
- Generation of HPV pseudovirions using transfection and their use in neutralization assays. (2005) (278)
- Maturation of Papillomavirus Capsids (2005) (278)
- The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding (2009) (269)
- A quantitative in vitro focus assay for bovine papilloma virus. (1980) (269)
- Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. (2006) (267)
- Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. (1982) (266)
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine (2011) (259)
- Papillomaviruses infect cells via a clathrin-dependent pathway. (2003) (253)
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. (2015) (252)
- Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. (2000) (252)
- Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. (2004) (247)
- Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. (1981) (241)
- An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue (1986) (238)
- A causal role for human papillomavirus in head and neck cancer (2004) (237)
- Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. (2001) (234)
- Identification of the HPV‐16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. (1987) (229)
- The Papillomavirus Minor Capsid Protein, L2, Induces Localization of the Major Capsid Protein, L1, and the Viral Transcription/Replication Protein, E2, to PML Oncogenic Domains (1998) (229)
- Papillomavirus polypeptides E6 and E7 are zinc-binding proteins (1989) (225)
- In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA (1980) (222)
- The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture (1991) (221)
- Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus (2008) (218)
- Helper-independent transformation by unintegrated Harvey sarcoma virus DNA (1978) (216)
- Nucleotide sequence of the p21 transforming protein of Harvey murine sarcoma virus. (1982) (206)
- Structure of endogenous murine leukemia virus DNA in mouse genomes. (1980) (206)
- Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. (1981) (204)
- Understanding and learning from the success of prophylactic human papillomavirus vaccines (2012) (203)
- DLC-1:a Rho GTPase-activating protein and tumour suppressor (2007) (203)
- Reducing HPV-Associated Cancer Globally (2012) (203)
- Identification and characterization of the neurofibromatosis type 1 protein product. (1991) (201)
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial (2013) (200)
- Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus (1980) (198)
- Human α-defensins block papillomavirus infection (2006) (198)
- Characterization of a human colon/lung carcinoma oncogene (1983) (197)
- Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection (2021) (197)
- Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. (1985) (195)
- Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. (2012) (194)
- Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities (2007) (190)
- Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles (2002) (189)
- Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles (2004) (189)
- Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. (2003) (187)
- Virus infection of murine teratocarcinoma stem cell lines (1977) (187)
- Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition (1996) (186)
- Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. (1985) (185)
- E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene (1986) (181)
- Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. (2005) (178)
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. (2011) (178)
- Mutational analysis of a ras catalytic domain (1986) (178)
- The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors (1989) (172)
- Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies (2008) (171)
- Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. (2003) (170)
- Mammalian and yeast ras gene products: biological function in their heterologous systems. (1985) (170)
- Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins (1994) (167)
- Interaction of papillomaviruses with the cell surface (1994) (166)
- Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1 (2005) (164)
- Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines (2009) (163)
- Studies of the mechanism of induction of infectious murine leukemia virus from AKR mouse embryo cell lines by 5-iododeoxyuridine and 5-bromodeoxyuridine. (1973) (162)
- In vivo mechanisms of vaccine-induced protection against HPV infection. (2010) (162)
- Identification of a second transforming region in bovine papillomavirus DNA. (1984) (162)
- Comparative biochemical properties of p21 ras molecules coded for by viral and cellular ras genes (1982) (153)
- Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. (2011) (153)
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. (2011) (153)
- Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. (1995) (149)
- Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. (2008) (147)
- Papillomavirus is resistant to desiccation. (1997) (147)
- Suppression of c-ras transformation by GTPase-activating protein (1990) (142)
- In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential (1991) (139)
- Human alpha-defensins block papillomavirus infection. (2006) (139)
- Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids (2008) (138)
- Inhibition of cell growth by lovastatin is independent of ras function. (1991) (135)
- Virus-specific transcription in bovine papillomavirus-transformed mouse cells. (1982) (131)
- Human papillomavirus infection and the primary and secondary prevention of cervical cancer (2008) (131)
- Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. (1993) (131)
- Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. (1980) (130)
- The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. (1988) (129)
- Genomes of murine leukemia viruses isolated from wild mice (1981) (128)
- Explanations for the high potency of HPV prophylactic vaccines (2018) (128)
- Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition (2007) (127)
- Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. (2012) (125)
- Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. (1975) (124)
- Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. (1999) (122)
- Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. (1982) (120)
- X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. (1985) (119)
- Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope (1997) (118)
- Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. (1985) (118)
- Papillomavirus-like particles and HPV vaccine development. (1996) (117)
- Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site (1982) (115)
- Identification of a Role for the trans-Golgi Network in Human Papillomavirus 16 Pseudovirus Infection (2013) (115)
- NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. (2001) (115)
- Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. (1975) (115)
- National Institutes of Health Consensus Development Conference Statement on Cervical Cancer (1997) (114)
- Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization (1979) (113)
- Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. (1995) (113)
- Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. (2009) (109)
- Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment (2016) (109)
- Friend strain of spleen focus-forming virus is a recombinant between ecotropic murine type C virus and the env gene region of xenotropic type C virus. (1977) (108)
- Dispersion of the ras family of transforming genes to four different chromosomes in man (1983) (107)
- Bovine papilloma virus-transformed cells contain multiple E2 proteins. (1988) (106)
- The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2‐dependent enhancer. (1988) (106)
- The Sos1 and Sos2 Ras‐specific exchange factors: differences in placental expression and signaling properties (2000) (104)
- Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK) (2011) (103)
- Isolation of Mouse Embryo Fibroblasts. (2013) (102)
- Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. (2005) (102)
- Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function (1994) (102)
- AKR murine leukemia virus genome: frequency of sequences in DNA of high-, low-, and non-virus-yielding mouse strains. (1974) (97)
- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies (2018) (97)
- Evidence that the AKR murine-leukemia-virus genome is complete in DNA of the high-virus AKR mouse and incomplete in the DNA of the "virus-negative" NIH mouse. (1974) (96)
- Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1. (1990) (95)
- Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: identification of a region related to Bcr, Vav, Dbl and CDC24. (1992) (94)
- Suppression of src transformation by overexpression of full-length GTPase-activating protein (GAP) or of the GAP C terminus (1991) (94)
- Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. (2016) (94)
- The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. (2009) (94)
- Ras-Specific Exchange Factor GRF: Oligomerization through Its Dbl Homology Domain and Calcium-Dependent Activation of Raf (1999) (90)
- Rrp1b, a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis (2007) (88)
- Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain (1993) (88)
- Antigen presentation and T-cell activation in epidermodysplasia verruciformis. (1990) (86)
- Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. (2003) (85)
- Vaccines to prevent infections by oncoviruses. (2010) (83)
- Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor (1995) (82)
- Positively Charged Termini of the L2 Minor Capsid Protein Are Necessary for Papillomavirus Infection (2001) (81)
- Identification of a 30S RNA with properties of a defective type C virus in murine cells (1978) (80)
- L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. (1998) (79)
- Raising expectations for subunit vaccine. (2015) (79)
- Functional organization of the Harvey murine sarcoma virus genome (1980) (78)
- Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. (1997) (78)
- Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment (2018) (78)
- p16INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB (2003) (78)
- L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation (2001) (78)
- Prospects for cervical cancer prevention by human papillomavirus vaccination. (2006) (77)
- New clue to Ras lipid glue (1989) (76)
- Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. (1996) (76)
- A Human Papillomavirus (HPV) In Vitro Neutralization Assay That Recapitulates the In Vitro Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies (2012) (76)
- Papillomavirus-like particle vaccines. (2000) (76)
- E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases (2010) (76)
- HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. (2005) (75)
- Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity (1992) (74)
- Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. (1996) (74)
- Aiming High--Changing the Trajectory for Cancer. (2016) (72)
- Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha interferon. (1984) (72)
- Nucleotide sequence of the 3' end of MCF 247 murine leukemia virus (1983) (71)
- Virus infection and human cancer: an overview. (2014) (71)
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial (2018) (68)
- p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities (2009) (68)
- Maturation of the Human Papillomavirus 16 Capsid (2014) (68)
- Mechanistic aspects of signaling through Ras in NIH 3T3 cells. (1992) (67)
- Papillomavirus-like particle based vaccines: cervical cancer and beyond (2001) (66)
- N Terminus of Sos1 Ras Exchange Factor: Critical Roles for the Dbl and Pleckstrin Homology Domains (1998) (66)
- Chapter 16: Prophylactic human papillomavirus vaccines. (2003) (64)
- Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity (1989) (62)
- HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. (2016) (61)
- Papillomavirus virus‐like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells (2005) (60)
- The COVID-19 Serology Studies Workshop: Recommendations and Challenges (2020) (60)
- The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment (2021) (59)
- Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. (2006) (58)
- Prognostic implications of HPV in oropharyngeal cancer. (2010) (58)
- Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by Mus musculus Papillomavirus 1 (2014) (58)
- Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. (2015) (58)
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. (2019) (58)
- Divergent human papillomavirus type 16 variants are serologically cross-reactive. (1995) (57)
- LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex (2016) (56)
- Prevention of cancer through immunization: Prospects and challenges for the 21st century (2007) (54)
- Papillomaviruses: prophylactic vaccine prospects. (1999) (54)
- Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. (2011) (54)
- Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial. (2020) (54)
- A new link between Fanconi anemia and human papillomavirus-associated malignancies. (2003) (53)
- Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus (2004) (52)
- Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). (2012) (52)
- The Expression of Glyceraldehyde-3-Phosphate Dehydrogenase Associated Cell Cycle (GACC) Genes Correlates with Cancer Stage and Poor Survival in Patients with Solid Tumors (2013) (52)
- Papillomaviruses and cervical cancer: pathogenesis and vaccine development. (1998) (51)
- Regulated and constitutive activity by CDC25Mm (GRF), a Ras-specific exchange factor (1993) (51)
- Restriction endonuclease mapping of ecotropic murine leukemia viral DNAs: size and sequence heterogeneity of the long terminal repeat. (1981) (51)
- CDK5 is a major regulator of the tumor suppressor DLC1 (2014) (50)
- Regulation of p21ras activity. (1991) (50)
- Retroviruses expressing different levels of the normal epidermal growth factor receptor: Biological properties and new bioassay (1989) (50)
- The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1. (2010) (49)
- The bovine papillomavirus E5 oncogene can cooperate with ras: identification of p21 amino acids critical for transformation by c-rasH but not v-rasH (1991) (49)
- Characterization of Mus musculus Papillomavirus 1 Infection In Situ Reveals an Unusual Pattern of Late Gene Expression and Capsid Protein Localization (2013) (47)
- Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015 (2016) (47)
- Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. (2013) (46)
- Early enhancement of calcium currents by H-ras oncoproteins injected into Hermissenda neurons. (1990) (45)
- Functional heterogeneity of proto-oncogene tyrosine kinases: the C terminus of the human epidermal growth factor receptor facilitates cell proliferation. (1989) (45)
- Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. (2012) (45)
- The transforming function of bovine papillomavirus DNA. (1983) (44)
- Some implications of the activation of murine leukemia virus by halogenated pyrimidines. (1972) (43)
- Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins (1994) (43)
- Amplification and rearrangement of onc genes in mammalian species (1982) (43)
- Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. (2012) (41)
- Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. (2012) (41)
- The biological activity of the human epidermal growth factor receptor is positively regulated by its C-terminal tyrosines. (1991) (40)
- Seroreactivity to HPV16 virus‐like particles as a marker for cervical cancer risk in high‐risk populations (1996) (40)
- p21-ras effector domain mutants constructed by "cassette" mutagenesis (1988) (40)
- Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses (2013) (37)
- Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles (2007) (37)
- Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. (2020) (36)
- Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo (1989) (36)
- The conserved C-terminal domain of the bovine papillomavirus E5 oncoprotein can associate with an alpha-adaptin-like molecule: a possible link between growth factor receptors and viral transformation (1993) (36)
- Transfected human beta-polymerase promoter contains a ras-responsive element (1990) (36)
- Topical Herpes Simplex Virus 2 (HSV-2) Vaccination with Human Papillomavirus Vectors Expressing gB/gD Ectodomains Induces Genital-Tissue-Resident Memory CD8+ T Cells and Reduces Genital Disease and Viral Shedding after HSV-2 Challenge (2014) (36)
- Transformation by cloned Harvey murine sarcoma virus DNA: efficiency increased by long terminal repeat DNA. (1980) (36)
- DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers (2016) (36)
- Subgenomic fragment of molecular cloned Friend murine leukemia virus DNA contains the gene(s) responsible for Friend murine leukemia virus-induced disease (1980) (35)
- Phylogenetic Considerations in Designing a Broadly Protective Multimeric L2 Vaccine (2013) (34)
- Transforming p21 ras protein: flexibility in the major variable region linking the catalytic and membrane‐anchoring domains. (1985) (33)
- Mapping of transforming region of the Harvey murine sarcoma virus genome by using insertion-deletion mutants constructed in vitro. (1980) (33)
- Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene (2003) (33)
- Inhibition of murine leukemia virus replication by poly(vinyluracil) and poly(vinyladenine). (1973) (32)
- Functional role of GTPase-activating protein in cell transformation by pp60v-src (1993) (32)
- Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia (2014) (32)
- Human papillomavirus capsids preferentially bind and infect tumor cells (2016) (32)
- Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA (2012) (31)
- Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. (2012) (30)
- The Ras-specific exchange factors mouse Sos1 (mSos1) and mSos2 are regulated differently: mSos2 contains ubiquitination signals absent in mSos1 (1997) (30)
- Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins (2018) (30)
- Heterogeneous amino acids in Ras and Rap1A specifying sensitivity to GAP proteins. (1991) (30)
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial. (2020) (29)
- Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma. (2009) (29)
- A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1 (1991) (29)
- Molecular cloning of the Harvey sarcoma virus circular DNA intermediates. II. Further structural analyses (1980) (28)
- In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (28)
- A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene (1989) (27)
- Adenylate cyclase activity of NIH 3T3 cells morphologically transformed by ras genes (1986) (27)
- A transforming ras gene can provide an essential function ordinarily supplied by an endogenous ras gene (1986) (27)
- Mutational analysis of bovine papillomavirus E6 gene (1989) (26)
- Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection (2019) (26)
- Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection (2020) (26)
- Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. (2020) (25)
- An Introduction to Virus Infections and Human Cancer. (2020) (25)
- Sequential Modification of Serines 621 and 624 in the Raf-1 Carboxyl Terminus Produces Alterations in Its Electrophoretic Mobility* (1997) (25)
- Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1 (2017) (25)
- Basic science: Bedrock of progress. (2016) (25)
- Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus (2014) (25)
- Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism (2017) (24)
- Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays (2014) (23)
- Mutant Feline Sarcoma Proviruses Containing the Viral Oncogene (v-fes) and Either Feline or Murine Control Elements (1983) (23)
- Papillomavirus Polypeptides E6andE7AreZinc-Binding Proteins (1989) (23)
- A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells (2019) (22)
- Chapter 1. Summary of IARC/NCI Expert Meeting on Primary End-points for Prophylactic HPV Vaccine Trials (2014) (22)
- Carcinogenesis: a fifty-year historical perspective. (1989) (21)
- TGFα enhances locomotion of cultured human keratinocytes (1993) (20)
- Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts. (1989) (19)
- In Vivo Longitudinal Imaging of Experimental Human Papillomavirus Infection in Mice with a Multicolor Fluorescence Mini-Endoscopy System (2011) (19)
- Tumorigenic transformation of NIH 3T3 cells by the autocrine synthesis of transforming growth factor alpha. (1991) (18)
- Cell transformation by ras and regulation of its protein product. (1993) (18)
- Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. (2014) (18)
- Selective potentiation of c-fps/fes transforming activity by a phosphatase inhibitor. (1990) (18)
- A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging (2015) (17)
- Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies (2007) (17)
- Concatenated Multitype L 2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines (2009) (16)
- Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020. (2021) (16)
- Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients1 (2009) (16)
- Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. (2015) (16)
- The Cdk5 activator P39 specifically links muskelin to myosin II and regulates stress fiber formation and actin organization in lens. (2015) (15)
- Early regulation of membrane excitability by ras oncogene proteins. (1990) (15)
- Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes (2019) (15)
- Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. (2018) (14)
- History of Papillomavirus Research (2007) (14)
- Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. (2014) (14)
- Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E‐cadherin/β‐catenin activity (2003) (13)
- Protein modification: new clue to Ras lipid glue. (1989) (13)
- Rational cancer therapy (1995) (13)
- Infectious murine leukemia virus from DNA of virus-negative AKR mouse embryo cells. (1978) (13)
- Rasp21 sequences opposite the nucleotide binding pocket are required for GRF-mediated nucleotide release. (1996) (13)
- In vitro transformation by bovine papillomavirus. (1984) (13)
- Human papillomavirus, cervical cancer prevention, and more. (2008) (13)
- Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids (2015) (12)
- Rrp 1 b , a New Candidate Susceptibility Gene for Breast Cancer Progression and Metastasis (2007) (12)
- The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane. (2015) (12)
- A Mutational Analysis of ras Function (1989) (12)
- Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions (2017) (11)
- Mutant p 53 Can Substitute for Human Papillomavirus Type 16 E 6 in Immortalization of Human Keratinocytes but Does Not Have E 6-Associated transActivation or Transforming Activity (11)
- Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function (2020) (10)
- Glucocorticoids induce focus formation and increase sarcoma viral expression in a mink cell line that contains a murine sarcoma viral genome (1978) (10)
- DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis (2019) (10)
- CDK 5 is a major regulator of the tumor suppressor DLC 1 (2014) (10)
- Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease. (2011) (9)
- TheFull-Length E6Protein ofHumanPapillomavirus Type16Has Transforming andtrans-Activating Activities andCooperates with E7ToImmortalize Keratinocytes inCulture (1991) (9)
- TGF alpha enhances locomotion of cultured human keratinocytes. (1993) (9)
- Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations. (2021) (9)
- The Partnership for Accelerating Cancer Therapies (2018) (8)
- Implementing the Cancer Moonshot and beyond. (2017) (8)
- Infections by human papillomavirus (warts). (1982) (8)
- SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions (2019) (8)
- Correction to Lancet Oncol 2015; 16: e227. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. (2015) (7)
- Molecular properties of a gag- pol- env+ murine leukemia virus from cultured AKR lymphoma cells (1982) (7)
- GUANINE NUCLEOTIDE BINDING ACTIVITY OF THE SRC GENE PRODUCT OF RAT‐DERIVED MURINE SARCOMA VIRUSES (1980) (7)
- Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay (2014) (7)
- Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection: 2017 Lasker-DeBakey Clinical Research Award (2017) (7)
- Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020 (2021) (7)
- Tumor viruses, oncogenes, and human cancer. (1984) (7)
- Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. (2001) (6)
- Further genetic localization of the transforming sequences of the p21 v-ras gene of Harvey murine sarcoma virus (1984) (6)
- Induction of Autoantibodies to CCR 5 in Macaques and Subsequent Effects upon Challenge with an R 5-Tropic Simian / Human Immunodeficiency Virus (2004) (6)
- The NIH-led research response to COVID-19 (2023) (6)
- Nonmelanoma skin cancer, melanomas, warts, and viral oncogenesis. (1984) (5)
- Interaction of interferon with chick embryo cells (2005) (5)
- Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial (2021) (5)
- type 16 variant-dependent neutralizing epitope . Characterization of a human papillomavirus (1997) (5)
- Cellular immunity to lymphocytic choriomeningitis virus determined by cytotoxicity in vitro. Abstr. (1972) (5)
- Transforming Genes of Bovine and Human Papillomaviruses (1989) (5)
- 16 – Human papillomavirus vaccines (2013) (5)
- Localization of the HPV-16 Minor Capsid Protein L2 by Difference Imaging (2005) (5)
- Inhibition of Leukemia Virus Replication by Vinyl Analogs of Polynucleotides (1973) (5)
- Accelerating progress: (2019) (5)
- Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World Data (2022) (4)
- Human papillomavirus biology. (1996) (4)
- DLC1: a tumor suppressor that regulates Rho signaling (2017) (4)
- HPV infection: future prospects. (1997) (4)
- Cancer moonshot countdown (2016) (4)
- Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors (2022) (4)
- The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1 (2021) (4)
- Non-selective analysis of the transformation of FR3T3 rat cells by bovine papillomavirus type 1: regulations of viral transcription associated with phenotypic transformation. (1990) (3)
- Risk Factors for NON-HPV16/18 Cervical Infections and Associated Lesions Among HPV-DNA-Negative Women Vaccinated Against HPV16/18 in the Costa Rica Vaccine Trial (CVT). (2020) (3)
- A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays (2022) (3)
- 30 – Human Papillomavirus Vaccines (2018) (3)
- High-Risk Human Papillomavirus Is Sexually Transmitted : Evidence from a Follow-Up Study of Virgins Starting Sexual Activity ( Intercourse ) 1 (2001) (3)
- Cancer vaccines (2022) (3)
- Chimeric papillomavirus particles. (1995) (2)
- Proceedings of the 33rd annual symposium on the biology of skin cutaneous oncogenic viruses. (1984) (2)
- Preventive Human Papillomavirus Vaccines (2004) (2)
- Mutational Analysis ofBovine Papillomavirus E6Gene (1989) (2)
- Structure and infectivity of integrated murine leukemia virus DNA. (1980) (2)
- Developmental History of HPV Prophylactic Vaccines (2011) (2)
- Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions (2022) (2)
- Oncogenes are here to stay. (1985) (2)
- INTERFERON INHIBITS BOVINE PAPILLOMAVIRUS TRANSFORMATION OF MOUSE CELLS AND INDUCES REVERSION OF ESTABLISHED TRANSFORMANTS (1982) (2)
- Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein (2021) (2)
- Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. (2022) (2)
- Perspectives on HPV Virus-Like ParticleVaccine Efficacy (2006) (2)
- Abstract 2184: Complex formation between the DLC1 START domain and Cav1 contributes to the tumor suppressor function of DLC1 (2011) (1)
- Abstract 5563: Harnessing pre-existing viral immunity for development of a broadly applicable tumor immunotherapy (2020) (1)
- Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases (2007) (1)
- Bovine papilloma virus-transformed cells contain multiple E 2 proteins ( gene expression / viral proteins / transactivation ) (1)
- CDK4/6 Inhibitors Induce Antitumor Immunity. (2017) (1)
- P21 ras Transforming Protein: Significance of the Carboxy Terminus (1985) (1)
- Abstract 4680: Efficacy of the HPV16/18 vaccine against cervical, anal, and oral HPV infection among women with and without previous HPV16/18 exposure (2015) (1)
- Performance of cervical screening a decade following HPV vaccination: The Costa Rica Vaccine Trial. (2022) (1)
- In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells (2013) (1)
- Gene expression patterns induced by HPV‐16 L1 VLP in leukocytes from vaccine recipients (2008) (1)
- Abstract 4359: Several cancer types are associated with increased expression and activity of the ECT2 RhoGEF and decreased expression and activity of the DLC1 RhoGAP, leading to increased RhoA activity (2018) (1)
- Genetics of Retrovirus Tumorigenicity (1986) (1)
- Activation of Dendritic Cells Papillomavirus-Like Particles Induce Acute SchillerFrye (2001) (1)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (1)
- Human papillomaviruses and cancer. (1993) (1)
- Aaron Lerner: a mentor and friend. (2007) (1)
- Abstract 4513: Targeting the DLC1 Rho-GAP tumor suppressor protein to treat solid tumors (2019) (1)
- Abstract 1574: CDK5 negatively regulates Rho by phosphorylating and activating the Rho-GAP and tumor suppressor functions of DLC1 (2014) (1)
- Electron cryo-microscopy of Human Papillomavirus Type 16 capsid (2014) (1)
- Abstract 4377: AKT positively regulates Rho-GTP by attenuating the GAP activity of the DLC1 tumor suppressor: a mechanistic study with translational implications (2016) (1)
- Proto-oncogene activation in lung cancer. (1988) (1)
- LB-15. A Trans-Governmental Collaborative Effort to Independently Evaluate SARS-CoV-2 Serology Assays Using Well-Characterized Sample Panels (2020) (0)
- Estimating human papillomavirus vaccine efficacy from a single-arm trial: Proof-of-principle in the Costa Rica Vaccine Trial. (2023) (0)
- HPV42, a "Low-Risk" Type, and Digital Papillary Adenocarcinoma. (2023) (0)
- Bivalent HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection (155.27) (2011) (0)
- Abstract 53: Promoting WHO's Cervical Cancer Elimination Goals ‘90-70-90' by Developing, Implementing, and Evaluating the ECHO Latin America (ECHO ELA) Program (2021) (0)
- Abstract IA001: Innovation and equity in cancer prevention and screening (2023) (0)
- Abstract 3912: cProSite: A web based interactive platform for on-line proteomics and phosphoproteomics data analysis (2022) (0)
- Abstract 4235: Phosphorylation of Serine 861 in the ECT2 guanine nucleotide exchange factor activates Rho family GTPases and is a biomarker for several tumor types (2019) (0)
- Abstract IA001: Ending cancer as we know it – for all (2023) (0)
- Supplement II: Abstracts of the international symposium on Skin Carcinogenesis in man and in experimental models. Heidelberg, 29–31 October 1991 (pp S61–S88) (1991) (0)
- NOTES Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids (cid:1) (2008) (0)
- Abstract 5522: Cancer-associated point mutant in the START domain of DLC1 encodes a protein attenuated for tumor suppressor activity and for binding both Caveolin-1 and PLCD1 but not for Rho-GAP activity (2018) (0)
- Abstract 1762: The START domain of the DLC1 tumor suppressor binds phosphatidylserine and two proteins, PLCD1 and Caveolin-1 (2019) (0)
- Selection, Characterization, Calibration, and Distribution of the U.S. Serology Standard for Anti-SARS-CoV-2 Antibody Detection (2022) (0)
- Reply to Nalin. (2015) (0)
- Human papillomavirus type 16 virus-like particles: Elisa to detect high risk HPV infection and potential for a preventive vaccine (1993) (0)
- Association of American Cancer Institutes (2020) (0)
- Abstract B93: Concatenated multitype L2 fusion proteins as prophylactic human papillomavirus vaccines (2008) (0)
- I mmunoprevention of Cervical Cancer (0)
- Treating Smoking in Cancer Patients: An Essential Component of Cancer Care—The New National Cancer Institute Tobacco Control Monograph (2022) (0)
- 30 Current and Future Vaccines to Prevent HPV-associated Cancers (2012) (0)
- MAPPING OF THE TRANSFORMING REGION OF HARVEY SARCOMA VIRUS GENOME USING INSERTION-DELETION MUTANTS CONSTRUCTED IN VITRO (1980) (0)
- 2 History of Papillomavirus Research (2017) (0)
- Expression and detection of endogenous mouse C-type RNA viruses (1974) (0)
- molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history (2022) (0)
- Abstract 1364: Direct phosphorylation and attenuation of the DLC1 tumor suppressor by SRC kinase: a new mechanism of SRC-dependent activation of Rho with translational implications (2017) (0)
- Molecular and Cellular Pathobiology Functional Interaction of Tumor Suppressor DLC 1 and Caveolin-1 in Cancer Cells (2012) (0)
- Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein (2022) (0)
- Abstract 1436: The Cdk5 activator p39 specifically links muskelin to myosin and regulates stress fiber organization and contraction (2011) (0)
- Abstract 3431: Epigenetic reactivation of the DLC1 tumor suppressor protein is a new approach for cancer treatment (2020) (0)
- Selected Abstracts (2001) (0)
- Abstract LE01: DISTINGUISHED LECTURE ON TARGETS FOR CANCER PREVENTION: Prevention of cervical cancer in current and future generations by HPV vaccination and other approaches (2008) (0)
- Abstract 2137: A high proportion of protein phosphorylation sites identified in CPTAC breast cancer and lung adenocarcinoma may result from direct phosphorylation by CDK1 (2020) (0)
- Abstract 2508: Targeting mutantKRAStumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein (2021) (0)
- Papilloma virus assembly occurs at distinct nuclear structures, with viral DNA encapsidation being dependent upon a non-structural viral protein (1998) (0)
- The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1 (2021) (0)
- Complete and incomplete endogenous murine leukemia virus genomes in high and low leukemic mice. Abstr. (1974) (0)
- Abstract 2586: Identification of cancer-associated RhoA mutants and analogous K-Ras mutants that induce gain-of function despite low GTP binding (2020) (0)
- Abstract IA11: Understanding and overcoming cancer disparities in the U.S. and abroad (2016) (0)
- Immunoprevention of Cervical Cancer (2005) (0)
- Abstract 1727: Cytoplasmic EZH2 and the DLC1 tumor suppressor are regulated by the CRM1 nuclear export protein and by specific complex formation between mutant KRAS and RAN-GAP (2023) (0)
- Abstract 3957: SRC inhibitors dephosphorylate and reactivate the DLC1 tumor suppressor: A new biomarker of clinical response (2018) (0)
- Abstract 888: Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms (2016) (0)
- The Burden of HPV-Associated Cancer in the Developing Versus Industrialized World (2011) (0)
- Abstract PL02-04: Drastically reducing HPV-associated cancers through etiologically-based primary and secondary prevention (2015) (0)
- Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment (2018) (0)
- AKR MurineLeukemia VirusGenome:Frequency ofSequences inDNA of High-, Low-, andNon-Virus-Yielding MouseStrains (RNAvirus/reassociation kinetics) (1974) (0)
- Papillomaviruses (1985) (0)
- Persistent Viremia Vaginal Acquisition andmac 251 from SIV T Cell Responses in Protection + and CD 8 + Antibody to the gp 120 V 1 / V 2 Loops and CD 4 Genoveffa (2014) (0)
- DNADelivering Simian Immunodeficiency Virus Papillomavirus Pseudovirion Vaccines Targeting the Vaginal Mucosa with Human (2011) (0)
- The crystal structure of R7R8 in complex with a DLC1 fragment. (2016) (0)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (0)
- Particles Conjugated Papillomavirus Virus-Like Determinants of Autoantibody Induction by Schiller (2002) (0)
- Clinical Evidence Generation During a Pandemic (2022) (0)
- Inactivation of the NFI gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTPRas (2005) (0)
- HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial (2022) (0)
- Mechanism of transcriptional enhancement by bovine papillomavirus e2 protein (1987) (0)
- CERVICAL CANCER: ITS CONTROL AND EVENTUAL ELIMINATION IN LOW- AND MIDDLE- (2019) (0)
- The ras gene family. (1986) (0)
- Potential oncogenic hazards posed by oncogene encoded proteins. (1987) (0)
- Capsid protein HPV1 recombinant papilloma virus that self-assemble. (1993) (0)
- Prospects for preventing cancer with anti-microbial prophylactic vaccines. (2022) (0)
- GUANINE NUCLEOTIDE BINDING ACTIVITY OF MURINE SARCOMA VIRUSES THE SRC GENE PRODUCT OF RAT-DERIVED (1980) (0)
- Abstract 2155: Inactivation of the tumor suppressor DLC1 by the oncogenes SRC and ERK1 in lung adenocarcinoma (2015) (0)
- Functional heterogeneity of proto-oncogene tyrosine kinases: the C terminus of the human epidermal growth factor receptor facilitates cell proliferation (1989) (0)
- Proceedings of the 1997 meeting of the Society for Pediatric Dermatology. (1998) (0)
- Serologic response to HPV16 capsids in women is associated with persistent HPV16 infection and increased cervical cancer risk (1994) (0)
- Abstract ED01-01: Preventing multiple types of cancer through HPV vaccination. (2011) (0)
- HPV AND CERVICAL CANCER: FROM PATHOGENESIS TO PREVENTION (1997) (0)
- CHARACTERIZATION OF FOUR DIVERGENT HUMAN GENOMIC CLONES HOMOLOGOUS TO THE TRANSFORMING P21 GENES OF HARVEY AND KIRSTEN MURINE SARCOMA VIRUSES (1982) (0)
This paper list is powered by the following services:
Other Resources About Douglas R. Lowy
What Schools Are Affiliated With Douglas R. Lowy?
Douglas R. Lowy is affiliated with the following schools:
